Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma

Main Article Content

NICOLA SGHERZA
PAOLA CURCI
VANDA STRAFELLA
RITA RIZZI
PELLEGRINO MUSTO

Keywords

multiple myeloma, COVID-19, IL-6, tocilizumab, siltuximab, sarilumab

Downloads

Download data is not yet available.
Abstract 110 | PDF Downloads 59

References

1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14. PMID: 32066541; PMCID: PMC7159000

2. Crisafulli S, Isgrò V, La Corte L, Atzeni F, Trifirò G. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. BioDrugs. 2020 Aug;34(4):415-422. doi: 10.1007/s40259-020-00430-1. PMID: 32557214; PMCID: PMC7299248

3. Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Pharmaceut Med. 2020 Aug;34(4):223-231. doi: 10.1007/s40290-020-00342-z. PMID: 32535732; PMCID: PMC7292936.
4. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig. 2020 Jun;40(6):511-518. doi: 10.1007/s40261-020-00917-3. PMID: 32337664; PMCID: PMC7183818.


5. Hirata T, Shimazaki C, Sumikuma T, Ashihara E, Goto H, Inaba T, Koishihara Y, Nakagawa M. Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro. Leuk Res. 2003 Apr;27(4):343-9. doi: 10.1016/s0145-2126(02)00179-0. PMID: 12531226.

6. Matsuyama Y, Nagashima T, Honne K, Kamata Y, Iwamoto M, Okazaki H, Sato K, Ozawa K, Minota S. Successful treatment of a patient with rheumatoid arthritis and IgA-κ multiple myeloma with tocilizumab. Intern Med. 2011;50(6):639-42. doi: 10.2169/internalmedicine.50.4636. Epub 2011 Mar 15. PMID: 21422694.